A recent study in eClinicalMedicine found that fecal microbiota transplantation, combined with fruquintinib and tislelizumab, significantly improved survival rates in patients with microsatellite stable metastatic colorectal cancer, showing manageable safety and notable increases in progression-free and overall survival.
Humana, Interwell Health Expand Value-Based Kidney Care Agreement to Florida
What You Should Know: – Humana Inc., a health and well-being company, and kidney care management company Interwell Health are expanding their value-based care agreement
September 24, 2024